28 related articles for article (PubMed ID: 6202772)
1. Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.
Brogden RN; Sorkin EM
Drugs; 1993 Oct; 46(4):652-77. PubMed ID: 7506651
[TBL] [Abstract][Full Text] [Related]
2. Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations.
Ratech H; Greco MA; Gallo G; Rimoin DL; Kamino H; Hirschhorn R
Am J Pathol; 1985 Jul; 120(1):157-69. PubMed ID: 4014441
[TBL] [Abstract][Full Text] [Related]
3. Adenosine-deaminase-associated immunodeficiency. I. Differential sensitivities of lymphocyte subpopulations exposed to 2-deoxycoformycin in vivo.
Bagasra O; Howeedy A; Pomerantz RJ
Clin Exp Immunol; 1992 Jun; 88(3):383-8. PubMed ID: 1535036
[TBL] [Abstract][Full Text] [Related]
4. Specific immunosuppressive effects of constant infusion of 2'-deoxycoformycin.
Trotta PP; Tedde A; Ikehara S; Pahwa R; Good RA; Balis ME
Cancer Res; 1981 Jun; 41(6):2189-96. PubMed ID: 6972248
[TBL] [Abstract][Full Text] [Related]
5. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and immunosuppressive activity of binary combinations of 2'-deoxycoformycin and 2'-deoxyadenosine.
Paine RM; Weston BJ; Clink HM; Kohn J; Neville AM; McGhee KG; Harrap KR
Cancer Treat Rep; 1981; 65(3-4):259-66. PubMed ID: 6972254
[TBL] [Abstract][Full Text] [Related]
7. 2'Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells.
Ruers TJ; Buurman WA; van der Linden CJ
J Immunol; 1987 Jan; 138(1):116-22. PubMed ID: 3097141
[TBL] [Abstract][Full Text] [Related]
8. Specificity of 2'-deoxycoformycin inhibition of adenosine metabolism in intact human skin fibroblasts.
Holland MJ
Res Commun Chem Pathol Pharmacol; 1986 Mar; 51(3):311-24. PubMed ID: 3486439
[TBL] [Abstract][Full Text] [Related]
9. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
Ratech H; Kim J; Asofsky R; Thorbecke GJ; Hirschhorn R
J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772
[TBL] [Abstract][Full Text] [Related]
10. 2'-deoxycoformycin. A new anticancer agent.
Poster DS; Penta JS; Bruno S; Macdonald JS
Cancer Clin Trials; 1981; 4(2):209-13. PubMed ID: 7018725
[TBL] [Abstract][Full Text] [Related]
11. Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases.
Spiers AS
Haematologia (Budap); 1996; 27(2):55-84. PubMed ID: 14651224
[TBL] [Abstract][Full Text] [Related]
12. Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors.
Ho AD; Ganeshaguru K
Klin Wochenschr; 1988 Jun; 66(11):467-74. PubMed ID: 2841534
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]